170 related articles for article (PubMed ID: 35871475)
1. Utilizing Deep Learning for Detecting Adverse Drug Events in Structured and Unstructured Regulatory Drug Data Sets.
Knisely BM; Hatim Q; Vaughn-Cooke M
Pharmaceut Med; 2022 Oct; 36(5):307-317. PubMed ID: 35871475
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
[TBL] [Abstract][Full Text] [Related]
3. Comparing drug safety of hepatitis C therapies using post-market data.
Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
[TBL] [Abstract][Full Text] [Related]
4. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
[TBL] [Abstract][Full Text] [Related]
6. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
7. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
8. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
10. Using natural language processing to characterize and predict homeopathic product-associated adverse events in consumer reviews: comparison to reports to FDA Adverse Event Reporting System (FAERS).
Konkel K; Oner N; Ahmed A; Jones SC; Berner ES; Zengul FD
J Am Med Inform Assoc; 2023 Dec; 31(1):70-78. PubMed ID: 37847653
[TBL] [Abstract][Full Text] [Related]
11. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
12. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Pediatric Reports in the US Food and Drug Administration Adverse Event Reporting System from 2010-2020: A Cross-Sectional Study.
Phan M; Cheng C; Dang V; Wu E; Muñoz MA
Ther Innov Regul Sci; 2023 Sep; 57(5):1062-1073. PubMed ID: 37351842
[TBL] [Abstract][Full Text] [Related]
14. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
[TBL] [Abstract][Full Text] [Related]
15. Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.
Schotland P; Racz R; Jackson DB; Soldatos TG; Levin R; Strauss DG; Burkhart K
Clin Pharmacol Ther; 2021 May; 109(5):1232-1243. PubMed ID: 33090463
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
Park S; Choi SH; Song YK; Kwon JW
JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
[TBL] [Abstract][Full Text] [Related]
17. Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS).
Xu R; Wang Q
J Biomed Inform; 2014 Feb; 47():171-7. PubMed ID: 24177320
[TBL] [Abstract][Full Text] [Related]
18. Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System.
Rogers JR; Sarpatwari A; Desai RJ; Bohn JM; Khan NF; Kesselheim AS; Fischer MA; Gagne JJ; Connolly JG
Drug Saf; 2019 Jan; 42(1):85-93. PubMed ID: 30066315
[TBL] [Abstract][Full Text] [Related]
19. Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives.
Polepalli Ramesh B; Belknap SM; Li Z; Frid N; West DP; Yu H
JMIR Med Inform; 2014 Jun; 2(1):e10. PubMed ID: 25600332
[TBL] [Abstract][Full Text] [Related]
20. Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System.
Kreimeyer K; Dang O; Spiker J; Muñoz MA; Rosner G; Ball R; Botsis T
Comput Biol Med; 2021 Aug; 135():104517. PubMed ID: 34130003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
